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Abstract
A tumor does not consist of a homogenous population of cancer cells. Therefore, to understand cancer, the tumor
microenvironment and the interplay between the different cell types present in the tumor has to be taken into
account, and how this regulates the growth and survival of the cancer cells. To achieve a full picture of this
complex interplay, analysis of tumor tissue should ideally be performed with cellular resolution, providing activity
status of individual cells in this heterogeneous population of different cell-types. In addition, in situ analysis
provides information on the architecture of the tissue wherein the cancer cells thrive, providing information of the
identity of neighboring cells that can be used to understand cell-cell communication. Herein we describe how
padlock probes and in situ PLA can be used for visualization of nucleic acids and protein activity, respectively,
directly in tissue sections, and their potential future role in personalized medicine.
Keywords: PLA, Padlock probes, Tumor microenvironment, Personalized medicine, Diagnosis, Prognosis
The cancer cell
Progression from a normal cell to a cancer cell usually
requires several genetic alterations including overexpres-
sion or alterations of oncogenes and loss of tumor sup-
pressor genes [1]. Whole genome sequencing studies
reveal that hundreds of genes are more or less frequently
mutated in cancer [2]. Most mutated genes are only
altered in a small subset of patients with a particular can-
cer disease, while only a few genes are commonly
mutated. However, collectively rare mutations make up a
large proportion of the mutational landscape of cancer.
While the DNA sequence acts as a blueprint in the mole-
cular assembly of an individual, the functionally active
components of a cell are RNA and proteins. Analysis of
RNA and protein are therefore needed to determine to
what extent the genetic information is utilized to pro-
mote growth and survival of cancer cells. However, the
question is whether genetic alterations propagating into
expressed RNA and proteins are the sole factor causing
and sustaining cancer, and how much this is influenced
by epigenetic alterations [3], or if there are additional
external factors. To what extent do cells determine their
own fates?
Cancer and microenvironment
For all multicellular organisms intercellular communica-
tion is essential to ensure proper organization of individual
cells in tissues and organs. The signals transferred between
cells provide information that determines the fate of the
recipient cells, regulating growth, survival and differentia-
tion. In order to decide to which signals they should
respond, cells express different panels of receptors that
subsequently will relay the signals, via intricate networks
of protein-protein interactions where the activity status of
the individual proteins are regulated by post-translational
modifications (PTMs). The observed genetic and epige-
netic alterations in cancer cells act to promote sustained
growth and survival and to overcome the growth restraints
from the surrounding cells. The extent of the interplay
between cell types, and the regulatory effects from the
neighboring cells on the phenotype of a cancer cell, is
maybe best exemplified by teratomas. When teratoma
cells are introduced into blastocysts of pseudo-pregnant
mice they will normalize their phenotype and generate a
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any medium, provided the original work is properly cited.mosaic that will be tumor free [4,5]. When teratoma cells
are instead transplanted into the sides of 129/SV mice,
they will form tumors. In fact, transplanting induced pluri-
potent stem cells (iPSC) into mice to form teratomas is
presently used as a step for assessing the validity and viabi-
lity of iPSC [6-8].
While the normal cells surrounding cancer cells some-
times fail to prevent the cancer from proliferating, this
prevention seemingly succeeds more often than it fails as
dormant and unnoticed cancer are developed throughout
life [9]. This was indicated already in 1934 when small
carcinoma was discovered at surprisingly high levels
(14%) in prostates of individuals exceeding 50 years of
age having died from unrelated causes [10]. The preva-
lence was discovered to be even higher (34%) in a later
study examining the entire prostate glands of even
younger males [11]. Apparently the pathogenic transfor-
mation of a cell into a carcinogenic state is not enough
for full-blown tumor growth. Functions external to the
cancer cell must somehow influence its capability to pro-
liferate. Thus, properties of the microenvironment have
been gaining interest when trying to understand what
activates carcinoma into proliferation. It is now evident
that cancerous tumors are not the homogeneous collec-
tions of cells they were once thought to be, but consists
of several types of cell subpopulations (reviewed by
Hanahan and Weinberg [12]). These are cancer cells,
cancer stem cells, endothelial cells, pericytes, immune
inflammatory cells, cancer-associated fibroblasts, and
stem and progenitor cells of the tumor stroma [12].
Together they make up the tumor microenvironment but
they have different origins, with the cancer cells acting as
tumor initiators. The stem and progenitor cells of the
tumor stroma, the immune inflammatory cells and the
bone marrow-derived vascular progenitor cells are all
recruited from circulation or neighboring tissues. This is
true also for the cancer-associated fibro-blasts, which can
be recruited myofibroblasts or reprogrammed variants of
normal tissue-derived fibroblastic cells. Inflammatory
cells can be attracted to the tumor by cancer cells which
sometimes undergo necrosis, instead of healthy apoptosis
[13,14], creating an inflammatory environment that can
both antagonize and promote the tumor growth, and in
this light tumors have been described as wounds that
never heal [15,16]. Formation of vasculature is regulated
by the balance between secreted pro- and anti-angiogenic
factors, supporting the cancer cells with nutrients and
oxygen. However, the tumor vessels display abnormal
organization that impairs transport of nutrients and oxy-
gen, and facilitates migration of cancer cells [17]. The
shuttling of cancer cells between the vascular system (i.e.
circulating tumor cells (CTC)) and the tumor tissue has
been suggested as an important event (i.e. cancer self-
seeding) that promotes the growth of a tumor, as the
cancer cells are adapted to the local microenvironment
[18]. Some of the CTC will fail in the homing to the local
microenvironment and will end up in circulation, where
they may colonize other sites, supported by interactions
with leukocytes that promote extravasation and survival,
giving rise to metastasis [19,20]. Immune cells and bone-
marrow derived progenitor cells have also been described
to promote angiogenesis in tumors [17,21]. Normal stro-
mal fibroblasts are now recognized as being able to
induce carcinomas through paracrine signaling with sev-
eral growth factors [22]. Mesenchymal stem cells can be
recruited to tumors and have been observed to differenti-
ate into several cell types in the tumor stroma, and to
exert both tumor promoting and suppressing functions
in contradicting studies [23]. The concept of cancer stem
cells has been widely used during the past few decades to
explain different phenotypes and abilities to generate
tumors within tumors. An alternative explanation to
such events is that the cancer cells experience high plasti-
city and that differences observed are contingent on the
position of the cells in the microenvironment [24,25], to
which they adapt to by epigenetic reprogramming, i.e.
epithelial-mesenchymal transition (EMT) and mesenchy-
mal-epithelial transition (MET). This is a not yet fully
understood program comprising the transition of epithe-
lial cells into cancerous states of varying degrees [12].
Hypoxia or overexpression of hypoxia-inducible factor-
1a (HIF-1a) has been shown to promote EMT and a
metastatic phenotype [26], suggesting that poor or defi-
cient vascularization of a tumor might induce cancer
stem cell properties. The transition into a mesenchymal
phenotype is accompanied by epigenetic alterations that
activate mesenchymal genes while expressions of epithe-
lial genes are suppressed. To allow repetitive transitions
between epithelial and mesenchymal phenotypes bivalent
modifications of the promoters by H3K4 methylation and
H2K27 trimethylation will keep genes downregulated
during EMT, but poised for activation in subsequent
MET [27].
It seems that the tumor microenvironment is highly
intricate, being made up from numerous cell types all
affecting each other in both pathological and normal
manners. How may we untangle these interactions
among cells and their internal constituents? What meth-
ods are needed?
Requirements on analytical methods
The deregulation of signals in cancer cells, promoting
growth and survival to later form tumors, can originate
from several levels; the DNA sequence, the epigenetic
status, the degree of gene and protein expression, and
also protein activity (interactions and post-translational
modifications (PTMs)). To obtain a coherent view of a
cell, analysis should ideally be performed at several
Clausson et al. EPMA Journal 2012, 3:7
http://www.epmajournal.com/content/3/1/7
Page 2 of 9levels in the same cell. In cancer research, xenografts
and cell lines are commonly used as cancer models in
the place of primary tumor material–a limited resource,
also complicated by heterogeneity in composition and
variation between samples. However, the usage of cancer
models involves artifacts. Concerning xenografts, the
mouse stroma may not support the growth of a human
tumor. For cell lines, normally grown in 2D mono cul-
tures on plastic support and having almost unlimited
supply of nutrients and oxygen, the adaptation (epige-
netic alterations) and evolution (selection of novel geno-
mic aberrations) caused by in vitro culturing, can
severely influence the phenotype of the cells [28,29].
However, there are areas of research where cell lines,
being homogenous populations and unlimited resources,
are suitable. One is in detailed studies of cell signaling
kinetics. But one needs to be careful drawing conclu-
sions from cell lines as representatives of tumors in
vivo, as the activity status of a cancer cell in vivo will be
dependent on where in a tumor it resides as this will
influence its exposure to signals, nutrients and oxygen.
The emerging view of the heterogeneous cancer micro-
environment highlights the need for single cell analysis.
Studies of the tumor microenvironment thus need to be
performed in clinical tissue samples, which closely
represent in vivo states. There are then two alternative
approaches: either to isolate the cells of interest and
perform the analyses in vitro or perform the analyses in
situ, keeping the architecture intact. By micro-dissecting
populations of cells, standard analytical methods may be
used. However, sensitivity demands increase with
decreasing amount of obtained material. In situ analysis
on the other hand targets the analyte directly in its nor-
mal location, omitting the need to collect cells and pur-
ify nucleic acids or proteins. For in situ analysis the
available methods are few, the most common ones are
fluorescence in situ hybridization (FISH) for analyzing
nucleic acids and immunohistochemistry (IHC) for pro-
tein detection. These methods are mainly based on the
use of probes such as oligonucleotides or antibodies and
as a consequence thereof, the selectivity becomes limited
due to the inherent crossreactivity of the probes that
may generate false positive signals. We will continue
with an in depth description of a few in situ methods
developed in our research groups that overcome this
problem by requiring multiple criteria to be fulfilled for
a positive identification, providing single-nucleotide dis-
crimination for detection of nucleic acid and the possi-
bility to visualize the active fraction of a protein, by
targeting protein interactions or PTMs. Moreover,
simultaneous detection of different biomolecules in situ
will help in the understanding of the complex function
and regulation of cells. An optimal tool would have the
ability to visualize different positions in a signaling
pathway and measure phenotypic variations, e.g. expres-
s i o n ,w i t h i nt oa c h i e v eam o r ec o m p l e t ep i c t u r eo v e r
what is going on inside a single cell.
Visualization and genotyping of nucleic acids
Detection of nucleic acids by hybridization of FISH
probes [30] has been used for decades but lacks the abil-
ity to discriminate between closely similar sequences. To
increase the selectivity over what the base pairing of a
single probe provides, padlock probes were developed
[31]. These are linear oligonucleotides of approximately
70 to 100 nucleotides in length with target-complemen-
tary 5’- and 3’- ends which constitute dual target recogni-
tion when both probe arms must hybridize correctly to
the target. When padlock probes hybridize to their cor-
rect target the ends of the padlock probe are brought
together in a head to tail orientation, with only a nick in
between. The nicks can be sealed by a DNA ligase to cre-
ate circles that are locked onto the target strands as pad-
locks [31]. This nick ligation will only occur if there is a
perfect match between probe and target at the ligation
junction, leaving mismatched probes unligated. Padlock
probes were recognized early on for being useful for in
situ analysis and the first published application demon-
strated genotyping of centromeric sequences [32] using
hapten or fluorescence labeled probes. However, with
this approach single molecules could not be detected
because of high background from unspecifically bound
probes. To be able to visualize individual padlock probes,
we later used rolling circle amplification (RCA) with the
probes as templates. RCA is an isothermal amplification
technique of circular DNA molecules that creates long
single-stranded DNA molecules with tandem repeats
complementary to the original circles [33], here being the
padlock probes. The contiguous RCA products will by
nature collapse into micrometer-sized DNA-bundles. By
targeting the RCA product with fluorophore-labeled oli-
gonucleotides, these can be visualized as bright objects
easily distinguishable over background fluorescence [34].
The RCA also selects for circularized padlock probes, as
only ligated probes can be amplified, which further
enhances the inherent selectivity of the assays. To facili-
tate the binding of the padlock probe to its target
sequence, the DNA needs to be enzymatically prepared
in situ, to create a single stranded stretch. This is
achieved by combining restriction enzyme digestion with
an exonuclease step for target preparation. The free 3’-
end of the target strand can then be utilized to prime the
RCA and it is thus important that this is located close to
the bound padlock probe, creating an RCA product that
will be an elongation of the targeted sequence (Figure 1).
The method was first described for genotyping of mito-
chondrial DNA (mtDNA) [35]. By having two padlock
probes, one for each genotype (designed with different
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distinguished from the mutant in both homo- and het-
eroplasmic cell lines as well as in fresh-frozen tissue sec-
tions [35].
Genotyping of transcripts and gene expression profil-
ing using padlock probes and RCA has been of great
i n t e r e s t .H o w e v e r ,d i r e c tR NA-templated ligation of
DNA padlock probes have been shown to be rather inef-
ficient [36,37]. We circumvented the limitation of poor
ligation efficiency on RNA molecules with a conversion
o ft h em R N Ai n t oc D N A[ 3 8 ] .I nb r i e f ,t h em e t h o di s
initiated by in situ reverse transcription using LNA-con-
taining primers, followed by digestion of the mRNA part
of the mRNA/cDNA duplex for creation of a single-
stranded target. Padlock probes are thereafter hybridized
to the cDNA transcripts and circularized upon absolute
complementarity to the correct targets and finally, RCA
is primed from the cDNA to create visible signals, as
Figure 1 Detection of nucleic acids with padlock probes. a A single stranded stretch of DNA containing the target site is generated by
enzymatic digestion of DNA or reverse transcription of RNA, producing a free 3’-end. b A perfect hybridization of a padlock probe will bring the
5’-and 3’- end of the padlock probe together (arrow), c as the gap is sealed by ligation a circular DNA molecule is created. d The free 3’-end of
the target sequence will act as a primer for RCA to produce a concatameric RCA-product, complementary to the padlock probe, to which
fluorescence-labeled detection oligonucleotides can hybridize, for visualization. e Detection of HER2 (green dots) and b-actin (red dots) transcripts
using padlock probes in fresh frozen tissue sections from breast cancer [38]. Nuclei are counter-stained with DAPI (blue), scale bar equals 50 μm.
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been widely used in several in situ hybridization studies
and are known to increase hybridization affinities
towards DNA and RNA [39,40]. In addition to substan-
tial improvement of the reverse transcription step, due
to increased hybridization efficiency, the LNA-contain-
ing cDNA primers also protect the RNA from break-
down by RNase H [41] - a feature herein utilized to
anchor the cDNA molecule to the mRNA throughout
the whole procedure. Padlock probes will not just yield
information about the genotype of the transcript, but
will also provide information on target localization in
the tissue and cell. The approach has sufficient resolu-
tion to detect point-mutations, splice-variations, and
fusion transcripts. Another advantage of analysis at the
RNA level, which is closer to the phenotype than DNA,
is that it provides information about whether the muta-
tion is expressed or over-expressed and whether the
w i l d - t y p ea l l e l ei sf u n c t i o n a l l yl o s t( e x p r e s s e dl o s s - o f -
heterozygosity). Thus, this RNA-based assay will also
capture effects of promoter and enhancer mutations,
epigenetic alterations caused by large chromosomal
rearrangements and miRNA effects on transcription.
Visualizing protein interactions and post-
translational modifications
The activity status of proteins is in most cases regulated
by PTMs, such as phosphorylation, which will cause
structural changes in the proteins and thereby expose
catalytic sites or promote interactions with other pro-
teins. For localized detection of protein interactions,
double-staining of proteins with IHC is commonly used.
Employing two binders targeting different proteins and
being differently labeled, the co-localized observation of
these infers interaction. However, the resolution of a
regular fluorescence microscope is 200-350 nm [42],
which is arguably far too inferior for a positive identifi-
cation of interacting molecules in a co-localization
assay. One approach to improve the detection of co-
localized antibody-coupled fluorophores is to utilize the
Förster resonance energy transfer (FRET) that occurs
between fluorophores with compatible excitation and
emission spectra. The phenomenon requires short dis-
tances, below 10 nm, and is dependent on the orienta-
tion of the fluoro-phores [43]. For detection of protein
interactions in tissue sections the fluorophores needs to
be coupled to antibodies targeting the interacting pair of
proteins [44,45]. However, the method is currently ham-
pered by low quantum yield, tissue autofluorescence and
over bleeding between fluorophores, making detection
of low abundant protein interactions challenging.
To obtain a method that retains the requirement for
proximal binding of antibodies to interacting proteins in
order to create a signal, as for FRET, but to also provide
potent signal amplification, the in situ proximity ligation
assay (in situ PLA) was developed [46]. The method uti-
lizes the distance constraints for ligation of two DNA
molecules into a reporter molecule and employs PLA-
probes which are chimeric molecules consisting of anti-
bodies, for recognizing the protein of interest, equipped
with conjugated single stranded oligonucleotides, for sub-
sequent detection purposes. Proximal binding of pairs of
PLA-probes to the same target will position the oligonu-
cleotides in close vicinity of each other, which guide the
hybridization of two subsequently added circularization
oligonucleotides that upon ligation will form a circular
DNA molecule. The formation of this DNA circle will
thus be strictly dependent on, and will function as a
reporter for, the proximal binding of a pair of PLA-
probes. In analogy to what is previously described for the
padlock probes, the proximity-dependent DNA circle can
t h e nb eu s e da sat e m p l a t ef o rR C A ,p r i m e db yaf r e e3 ’-
end on one of the PLA-probes, to create an RCA product
that will be an elongation of the PLA-probe. The RCA
products are visualized with detection oligonucleotides
and will be localized close to the protein interaction of
interest as they are attached to the PLA probe, which still
binds its protein target (Figure 2). The method may be
used both to detect protein complexes, by targeting two
interacting proteins [46,47], and to determine post-trans-
lational modifications of a protein, targeting the core pro-
tein and a modified epitope [48]. A big advantage is that
the bright signals enable detection in formalin-fixed par-
affin-embedded tissue sections [49], which commonly
suffers from high autofluorescence. To circumvent auto-
fluorescence entirely, it is possible to replace the fluoro-
phore of the detection oligonucleotide with an enzyme,
providing an assay for protein interaction analysis by reg-
ular brightfield microscopy [50].
Although the distance requirement to generate an in
situ PLA signal is theoretically within ~20 nm (calculated
from the size of an antibody and length of the nucleo-
tides), the RCA product produced has a diameter of
approximately 1 μm. While the size of the RCA products
provides for easy detection, due to the high number of
repetitive targets for fluorophore-labeled detection oligo-
nucleotides, it also limits the number of RCA products
that can be detected in a cell. A few hundred RCA pro-
ducts per cell are often enough to cause saturation, when
discrete objects can no longer be defined. To increase the
limited dynamic range it is possible to use a mix of differ-
ent circularization oligonucleotides, with different
sequences for detection oligonucleotides, such that the
concentration ratio of the added circularization oligonu-
cleotides will then be reflected among the RCA products.
In practice, the effect is that when one type of RCA pro-
duct labeled with a distinct detection oligonucleotide
saturates the area of analysis, it is possible to instead view
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Page 5 of 9Figure 2 Detection of protein interactions with in situ PLA. a Proximal binding of PLA-probes to interacting proteins will guide the b
hybridization of circularization probes, c allowing them to be connected by ligation (arrows) and thereby creating a circular reporter molecule of
the protein interaction. d The oligonucleotide on one of the PLA-probes will then act as primer for RCA to generate an RCA product that will be
an elongation of the PLA-probe. Fluorescence-labeled detection oligonucleotides are then used to visualize the RCA-product. e Detection of
Mucin2 glycosylation (Sialyl-Tn) (red dots) in formalin-fixed paraffin-embedded tissue sections from intestinal metaplasia [49]. Nuclei are
counterstained with Hoechst 33342 (blue), using the autofluorescence of the tissue (green) to visualize the histology, scale bar equals 50 μm.
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oligonucleotide used at a lower concentration, which will
be reported by its respective other fluorophore-labeled
detection oligonucleotide. By viewing the type of RCA
products that are within the optimal dynamic range for
each cell, it is possible to simultaneously measure in situ
PLA targets in tissue sections containing cells with both
high and low levels [51].
Combined visualization of nucleic acids and
proteins
For visualization of interactions between protein and
nucleic acid (PNI), to visualize e.g. epigenetic status of
individual genomic sequences, things get more compli-
cated as probes targeting both types of biomolecules are
needed. To detect a specific DNA-sequence and its co-
localization with a particular protein, immunofluorescence
(IF) and FISH can be combined to form methods named
immuno-DNA FISH and immuno-RNA FISH [52-54].
The protein of interest is targeted with fluorescence-
labeled antibodies, while DNA is denatured and the target
sequence detected by hybridization of hapten-labeled
detection oligonucleotides. These haptens can in turn be
detected by IF through utilizing antibodies targeting the
hapten label. By superimposing the different fluorescence
channels, co-localization of the nucleic acid sequence and
the protein can be detected and visualized in situ.
Although immuno-DNA/RNA FISH presents a valuable
tool for investigation of PNIs in situ, spatial resolution is
restricted to the resolution of the microscope used and
proteins can only be detected if they are expressed at a
certain level or above for IF to distinguish them over back-
ground fluorescence. Furthermore, the method cannot dis-
tinguish between highly homologous sequences as it is
based on hybridization of a detection oligonucleotide. To
increase the selectivity, enabling detection of protein-DNA
interaction with an SNP-resolution, we developed a
method that is based on padlock probes to target the
DNA. Upon ligation, the padlock probe is converted into a
circularization probe that will be utilized to survey the
vicinity for bound PLA-probes. In order to prevent bind-
ing of the padlock probe to free PLA-probe, due to
sequence complementarity, the padlock probe was
equipped with hairpin structures that would hide the com-
plementary sequences during PLA-probe staining. After
washes the padlock probes can be activated, by degrading
the uracil containing hairpins, thereby enabling hybridiza-
tion to the bound PLA-probes [55]. After ligation the
amplification and detection can be performed as for con-
ventional in situ PLA. With this method we were able to
detect proximity between histone H3 and Alu-repeats in
human cells. Although the method was demonstrated to
be highly selective in discriminating between closely
homologous sequences (human and mouse Alu-repeats),
it suffers from poor efficiency in targeting genomic DNA.
Further efforts to make genomic DNA more accessible, i.e.
by alternative fixations and sample pretreatments, are
required to enable studies of single copy genes.
The prospect of personalized medicine
Although both padlock probes and in situ PLA are
recently developed methods, we have high hopes that
t h e yw i t h i nan e a rf u t u r ew i l lb ea d o p t e df o rr o u t i n e
diagnostics, just as IHC and FISH has become. A big
advantage with in situ assays is that they do not require
sophisticated and expensive equipment, both assays
based on padlock probes and in situ PLA can be used
with standard epifluorescence microscopes or, if the
RCA-products are developed into chromogenic signals,
even brightfield microscopes [50]. In situ analysis with
padlock probes can be a rapid test for detection of recur-
rent mutations that might be useful to guide e.g. therapy
choice, and the ability to genotype individual cells in a
tumor provides the means to determine clonal evolution.
To evaluate the functional consequences different muta-
tions will have on a cell, in situ PLA can be used to deter-
mine how these mutations effects the proteins ability to
interact with its partners. As mutations often occur at
different proteins in a signaling pathway, by monitoring
downstream hubs in signaling pathways all mutations
with a similar consequence will be detected. In addition,
as in situ PLA can be used on both cultured cells and tis-
sue sections, the same assay can be used for drug devel-
opment [56], diagnosis, selection of therapy and to
monitor therapy response.
Considering the complexity of a tumor, the key factor
for successful diagnostic assays lies in to what extent they
can provide a coherent view of the cellular processes gov-
erning the growth and survival of the cancer cells. Meth-
ods to determine activity status of proteins, to analyze
nucleic acids with a higher resolution and to determine
interactions between these types of biomolecules at a sin-
gle cell level will most likely be pivotal for future molecu-
lar pathology as they provide a tool to address cell-cell
communication in the complex microenvironment of
cancer. By understanding these processes, along with the
ability for better characterization of individual patients,
new routes for personalized treatment strategies will
open up. Although cancer cells become addicted to the
growth promoting signals derived from a mutated signal-
ing pathway they still possess the ability to respond to
other signals. The heterogeneity within the clone, and
contacts with different cells and microenvironment of
each individual cancer cells, provide escaperoutes when
drugs are used to target one deregulated pathway. Single
agent treatment strategies would thus probably have very
limited success in eradicating all malignant cells within a
patient. Hence, other growth and survival promoting
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altered by a mutation. An inherent restriction of single
cell analyses is that the possibility to perform repetitive
analysis on the same cell is limited. Because of this, mul-
tiplexed analyses are requested in order to obtain as
much information as possible from each cell, and we
have therefore been working on approaches to multiplex
in situ PLA (Leuchowius et al., submitted). As padlock
probes and in situ PLA utilize the same read-out–visuali-
zation of RCA products–it is possible to combine these
methods for simultaneous detection of proteins and
nucleic acids [57]. This provides a tool for investigation
of active signaling both at the levels of signal transduc-
tion and expression of target genes.
As discussed previously, the interplay between the dif-
ferent cell types in a tumor will very likely have a major
role on the outcome of all individual cancers and meth-
ods that identify patients with an adverse tumor cell
communication will be important for prediction of dis-
ease and selection of therapy. The aberrant vessels
formed by tumor angiogenesis may have a larger role in
promoting growth of cancers than supporting them with
nutrients and oxygen (something that they actually are
deficient in), as the loosely assembled vessel walls facili-
tate intra- and extravasation of cancer cells. This will
increase the possibility that CTC home to adjacent sites
rather than forming distal metastasis. The hypoxic
environment, due to insufficient organization of the
tumor vessels, induces EMT that provides the cancer
cells with a more motile phenotype. Both padlock
probes and in situ PLA will very likely have a substantial
role in elucidating the mechanisms involved in the cellu-
lar communications in tumors, something that then can
be adopted for personalized medicine to predict disease
progression, and in development and selection of ther-
apy to restore the tumor microenvironment to a state
that does not promote cancer growth. Albeit in situ
PLA analysis of epigenetic alterations of individual pro-
moters is not feasible at the moment, improvement in
efficiency of the padlock-based in situ PLA [55] might
soon provide a tool to investigate epigenetic reprogram-
ming of cancer cells during transitions between epithe-
lial and mesenchymal phenotypes.
Methods for analysis of cancer microenvironments
will most likely have a large impact on personalized
medicine and, although still early, the methods
described herein may provide new opportunities to bet-
ter predict disease progression and therapy response.
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